Head-To-Head Analysis: Odonate Therapeutics (ODT) versus Emergent BioSolutions (EBS)

Odonate Therapeutics (NASDAQ: ODT) and Emergent BioSolutions (NYSE:EBS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Insider and Institutional Ownership

80.4% of Odonate Therapeutics shares are held by institutional investors. Comparatively, 83.3% of Emergent BioSolutions shares are held by institutional investors. 16.5% of Emergent BioSolutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


This table compares Odonate Therapeutics and Emergent BioSolutions’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Odonate Therapeutics N/A N/A N/A
Emergent BioSolutions 11.96% 10.39% 7.74%

Analyst Recommendations

This is a breakdown of recent recommendations for Odonate Therapeutics and Emergent BioSolutions, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Odonate Therapeutics 0 1 2 0 2.67
Emergent BioSolutions 0 2 2 0 2.50

Odonate Therapeutics currently has a consensus price target of $33.50, suggesting a potential upside of 38.03%. Emergent BioSolutions has a consensus price target of $56.00, suggesting a potential upside of 10.58%. Given Odonate Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Odonate Therapeutics is more favorable than Emergent BioSolutions.

Valuation and Earnings

This table compares Odonate Therapeutics and Emergent BioSolutions’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Odonate Therapeutics N/A N/A -$32.74 million ($2.31) -10.51
Emergent BioSolutions $560.87 million 4.50 $82.59 million $1.90 26.65

Emergent BioSolutions has higher revenue and earnings than Odonate Therapeutics. Odonate Therapeutics is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.


Emergent BioSolutions beats Odonate Therapeutics on 9 of the 11 factors compared between the two stocks.

Odonate Therapeutics Company Profile

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc. also conducting a Phase III study in MBC, which is known as CONTESSA. The company was founded in 2013 and is based in San Diego, California.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The company offers BioThrax, an anthrax vaccine; ACAM2000, a Smallpox Vaccine; Raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. It also provides reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. The company's product candidates include NuThrax, a next generation anthrax vaccine; VLA1601, for the treatment of Zika virus; UNI-FLU, an influenza vaccine; EBX-205, an oral therapeutic to treat acute bacterial skin and skin structure infection; GC-072 for treating Burkholderia pseudomallei infection; EBI-001, a pan respiratory antiviral; FLU-IG (NP025) for the treatment of seasonal influenza; ZIKA-IG (NP024) for Zika infections; and FILOV (NP026) for treating treat hemorrhagic fever caused by Filoviruses. In addition, it provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply